- Home
- Equipment
- usa new york
- phase 1 clinical
Refine by
Phase 1 Clinical Equipment Supplied In Usa New York
13 equipment items found
Manufactured by:Acorda Therapeutics, Inc. based inPearl River, NEW YORK (USA)
GGF2 is a member of the neuregulin growth factor family, and has been shown to promote recovery after neurological injury, as well as to enhance heart function in animal models of heart failure. GGF2 showed positive effects on cardiac function in the two Phase 1 clinical studies conducted to date. The Phase 1b trial ...
Manufactured by:Auro Vaccines LLC based inPearl River, NEW YORK (USA)
The Auro Vaccines discovery engine is rapidly creating a pipeline of differentiated new vaccines. On the leading edge of development ...
Manufactured by:Auro Vaccines LLC based inPearl River, NEW YORK (USA)
As part of its comprehensive Public Health and Biodefense vaccine franchise, under a license from the Henry M. Jackson Foundation, Auro Vaccines is developing a subunit vaccine (HeV-sG-V) composed of the envelope glycoprotein of Hendra virus for the prevention of Nipah virus (NiV) ...
Manufactured by:S1 Biopharma, Inc. based inNew York City, NEW YORK (USA)
S1 Biopharma’s first-in-class lead product, Lorexys, targets hypoactive sexual desire disorder (HSDD) in women, the most common type of female sexual dysfunction. Lorexys is designed to restore the balance of three neurotransmitters – dopamine, serotonin and norepinephrine – that are known to regulate sexual inhibition and sexual excitation. An oral, non-hormonal, fixed-dose ...
Manufactured by:Vitalis, LLC based inNew York, NEW YORK (USA)
VTS-72 aims to be the next generation oral fumarate therapy, that may hold potential as a treatment for RRMS with fewer side effects and other clinical benefits for these ...
Manufactured by:Auro Vaccines LLC based inPearl River, NEW YORK (USA)
Auro Vaccines has developed a VesiculoVax™-vectored vaccine to protect against the arthralgic disease caused by infection with Chikungunya ...
Manufactured by:Auro Vaccines LLC based inPearl River, NEW YORK (USA)
Auro Vaccines has developed VesiculoVax™-vectored vaccines for pre- and post-exposure protection against the hemorrhagic disease caused by multiple species of filovirus (i.e. Zaire ebolavirus, Sudan ebolavirus and Marburg ...
Manufactured by:Auro Vaccines LLC based inPearl River, NEW YORK (USA)
Auro Vaccines is developing a GeneVax prime/VesiculoVax boost therapeutic HPV vaccine for use as an adjunct to surgery that targets the seven HPV types responsible for more than 92% of cervical and head and neck ...
by:Curemark based inRye Brook, NEW YORK (USA)
The U.S. Centers for Disease Control and Prevention estimate that 1 in 68 children in the United States have been diagnosed with Autism. There is currently no approved drug on the market that treats the core symptoms of Autism. At Curemark, we are working to change that. Curemark’s lead drug candidate, CM-AT, has received “Fast Track” designation from the U.S. Food and Drug ...
Manufactured by:Auro Vaccines LLC based inPearl River, NEW YORK (USA)
Auro Vaccines has developed a VesiculoVax™-vectored vaccine to protect against Lassa hemorrhagic ...
Manufactured by:Pluristem Therapeutics Inc. based inHaifa, ISRAEL
PLX-PAD cells exhibit regenerative potential due to their capacity to release factors in response to chemical distress signals from tissues that have been damaged by muscle trauma or inflammation. These therapeutic factors trigger the body’s repair mechanisms and stimulate tissue renewal, differentiation and modulation of immune-mediated inflammation. PLX-PAD cells also modulate the immune ...
Manufactured by:Pluristem Therapeutics Inc. based inHaifa, ISRAEL
PLX-R18 cells release a combination of therapeutic proteins in response to a damaged or poorly functioning hematopoietic system; this system creates the blood cells that protect us from infection, uncontrolled bleeding and anemia. PLX-R18 is currently in a Phase I clinical trial to treat incomplete hematopoietic recovery following Hematopoietic Cell Transplantation (HCT) and in development to ...
Manufactured by:Mesoblast Ltd. based inMelbourne, AUSTRALIA
Revascor is a Phase 3 product candidate being developed as a treatment for both advanced and end-stage chronic heart failure ...